ADS-ADEA 2016* Clinical Science
Chair: Samantha Hocking
Quantifying and Predicting Mean A1C Reductions for Exenatide QW and BID: Importance of Baseline A1C and Other Patient Characteristics (#56)
3:30 PM
Addition or Switch to Insulin Therapy in Patients Treated with GLP-1 Receptor Agonists: A Real World Study in 66,583 Patients (#57)
3:45 PM
Hypoglycaemia in Elderly Patients with Type 2 Diabetes in Subacute Hospital Care is Associated with increased Mortality (#58)
4:00 PM
Audit of Diabetes Management Guidelines for the Cancer Centre during the Pilot Phase (#59)
4:15 PM
Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG OUTCOME (#60)
4:30 PM
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial outcomes (#61)
4:45 PM
Effects of linagliptin on glycemic control and albuminuria in type 2 diabetes - the MARLINA–T2D™ trial (#62)
5:00 PM
Fenofibrate Reduces Uric Acid Levels and Gout Events in Type 2 Diabetes: Results from the Field Study (#63)
5:15 PM